Nearly a decade after the anti-NGF class of pain drugs was crushed by safety issues and then began a long, agonizingly slow return to late-stage testing, it may all be over soon. Pfizer and Eli Lilly posted a set of longterm outcomes from a Phase III study of tanezumab, and once they got a glimpse of the data analysts immediately started to pen last rites for the drug.
A rival therapy from Regeneron and Teva isn’t being given good odds of survival.
There were mixed efficacy results for the Pfizer/Lilly program, with only the high dose achieving a statistically significant improvement for pain and physical function over NSAIDS. And the pain data were alarming, reflecting earlier concerns spotlighted by researchers.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription